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1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive inflammation
of the airways and is one of the major causes of death in the elderly. COPD leads to develop‐
ment of airflow limitation as evident by decreased forced expiratory volume in one second
(FEV1) and reduction in the percentage of FEV1/ vital capacity. Standardised spirometric tests
showing the presence of airflow obstruction are used in clinical diagnosis and more recently
the use of high resolution CT scanning has been employed to detect early emphysematous
changes which may be present prior to severe airflow obstruction (Figure 1).
In the lungs of patients with COPD elevated levels of pro-inflammatory cytokines such as
interleukin (IL)-8, leukotriene-B4 (LTB4) and tumour necrosis factor-α (TNFα) have been
recorded which can act as neutrophil chemoattractants. Once recruited to the airways,
neutrophils are activated and release various compounds including reactive oxygen species,
proteases and cationic proteins in order to clear infections. When released in excessive amounts
however, these molecules can cause extensive damage to the respiratory epithelium resulting
in yet more pro-inflammatory cytokine release and further neutrophil influx, thereby creating
a cycle of inflammation.
It  is  now  clear  that  neutrophil  serine  proteases,  including  neutrophil  elastase  (NE),
proteinase 3 (PR3) and cathepsin G (CathG) are major pathogenic determinants in chron‐
ic  airway  inflammatory  disorders.  Moreover,  accumulating  evidence  indicates  that  the
expression of matrix metalloproteases (MMPs) is dysregulated in COPD and these proteins
are  involved  in  small  airway  remodelling.  Increased  levels  of  both  MMPs  and  serine
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proteases  can  participate  in  proteolytic  attack  on  the  alveolar  wall  matrix  and,  as  a
consequence  the  lung extracellular  matrix  is  damaged,  resulting  in  obstruction of  small
airways and development of emphysema.
Due to their implication in the pathology of COPD airways disease both MMPs and serine
proteases have been in focus for drug-development efforts over the last two decades. Such
concepts are further reinforced by scientific findings indicating that a variety of broad
spectrum serine protease and MMP inhibitors significantly ameliorate emphysema in experi‐
mental animal models of COPD. To this end, in recent years continued efforts to identify and
optimize novel mechanism-based inhibitors have led to a number of new inhibitors being
reported. For example three natural protease inhibitors, secretory leucocyte protease inhibitor
(SLPI), elafin and alpha-1 antitrypsin (AAT), have therapeutic potential for reducing the
protease-induced inflammatory response and show promising potency and selectivity
profiles. Other therapy options for the modulation of inflammation associated with excessive
protease activity is the use of recombinant, synthetic or semi synthetic protease inhibitors. In
this chapter we aim to describe the clinical and scientific evidence for the involvement of
proteases and their proposed mode of action in COPD development and progression. Potential
intervention with natural or synthetic inhibitors in the management of emphysematous
symptoms associated with COPD will be reviewed in this chapter.
Figure 1. Chest high resolution CT scan of COPD. A) A single slice from a high resolution CT (HRCT) scan of thorax
demonstrating normal healthy lung parenchyma. B) A single HRCT thorax image of the upper lobes demonstrating
loss of lung density in keeping with emphysematous change. C) Severe emphysema of the upper lobes showing mark‐
edly reduced lung density and bullous disease present (indicated by the arrow).
2. The role of proteases in COPD
There are several classes of proteases and these include serine-, cysteine-, aspartate-, threonine-
proteases and metalloproteases. For the purpose of this chapter we will focus on proteases
which have been implicated in the pathogenesis of COPD and discuss particularly serine
proteases and metalloproteases including NE, PR3, cathepsins and matrix metalloproteases.
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2.1. Serine proteases
Serine proteases are a class of proteases which are involved in various physiological and
pathological processes throughout the body and universally contain a serine as the amino acid
at the active site of the enzyme [1]. Serine proteases include NE, CathG and PR3. They are
primarily inactivated by serine protease inhibitors, the archetypal member of this family being
AAT [2]. The main model for the protease-antiprotease imbalance is AAT deficiency, thus
providing us with an insight into the importance of proteases in the development of emphy‐
sema [3, 4].
NE, PR3 and CathG are produced during neutrophil development in the bone marrow and
are stored in the azurophilic (primary) granules of neutrophils [5]. These serine proteases are
found in high concentrations in airway secretions of patients with inflammatory lung condi‐
tions [6, 7] and are seen in the circulating plasma of patients with severe sepsis and acute
respiratory distress syndrome [8]. They have effects upon a broad range of extracellular matrix
proteins including elastin, collagens, fibronectin, proteoglycans and laminin [9, 10]. Apart from
AAT deficiency a large number of experimental animal studies also support the role of the
protease/antiprotease imbalance in the pathogenesis of COPD, including the involvement of
NE and PR3 in the development of emphysema [11, 12].
2.1.1. The serine protease neutrophil elastase
NE is a single polypeptide glycoprotein comprising 218 amino acids and is quite homologous
with other serine proteases including PR3 and CathG [13]. NE is stored in the primary granules
of neutrophils and when neutrophils are activated or primed by cytokines, it is released from
the cell to the extracellular environment and may also rebind and become expressed on the
cell surface [14]. The activity of NE is primarily inhibited and regulated by AAT [2, 15] but
other inhibitors of NE have been reported including monocyte neutrophil elastase inhibitor
(MNEI/Serpin B1) [16], elafin [17, 18] and SLPI [19, 20]. Of interest, the converse has also been
shown whereby NE has been shown to inactivate and cleave SLPI. [21]
Smoking may lead to an imbalance between proteases and antiproteases through the reduction
of the functional activity of AAT in the lung and also as described earlier by increasing the
number of proteases produced hence increasing the proportion of elastolysis in the lung.
Moreover, cigarette smoke has been reported to inhibit the anti-NE activity of AAT in
bronchoalveolar lavage (BAL) fluid of smokers compared to healthy non-smoking control
subjects [22, 23], however some studies have argued against this point [24, 25]. Cigarette smoke
has also been shown to induce the release of NE in BAL fluid [26] and also to increase the
circulating NE levels seen in plasma [27]. This implicates NE in the pathogenesis of emphysema
and studies in BAL from COPD patients demonstrated a direct correlation between the NE
burden in BAL and the degree of emphysema seen on CT scans. Further to this, results showed
an inverse relationship between the anti-elastase activity in the BAL of COPD patients and the
degree of emphysema and diffusing capacity, supporting the protease-antiprotease imbalance
theory of emphysema [28].
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Further studies on the presence of NE in the airways have shown that NE can cleave a number
of epithelial cell surface receptors [29], cell activators and signalling cytokines [30] thereby
potentially orchestrating the airway inflammatory milieu. Moreover, data have shown that
alveolar macrophages may bind and internalise NE [31] and a later study has reported
increased levels of NE in alveolar macrophages of patients with emphysema, providing further
evidence of the increased protease burden [32]. NE has also been demonstrated using immu‐
nohistochemistry to be localised to the elastin fibres in the lung parenchyma of patients with
emphysema [33]. The theory of NE induced emphysema has been supported not only from
human studies but excellent animal models. Indeed, tracheal instillation of NE has been shown
to induce the infiltration of neutrophils into the lung and cause emphysema in experimental
models [11, 34].
Apart from the well-known role of NE as a protease in the protease/antiprotease imbalance in
emphysema it exerts additional effects which contribute to the pathogenesis of COPD. For
example NE exposure has been shown to significantly increase macrophage production of
cathepsin B and latent and active MMP-2 [35], whilst the addition of AAT to BAL fluid greatly
reduced NE-induced cathepsin B and MMP-2 expression in macrophages in vitro [36].
Additionally, NE is involved in the hypersecretion of mucus seen in COPD and is also a
secretagogue, inducing the submucosal gland cells and goblet cells to secrete mucus [37-39].
NE has been shown to induce the expression of MUC5AC at the gene level in epithelial cells
and hence increase the production of mucin in the airway. This mechanism has been shown
to be dependent on the presence of reaction oxygen species, linking the role of NE inducing
mucus hypersecretion to smoking [40, 41]. Moreover, not only does NE increase the amount
of mucus produced in the lung but it also interrupts the mucociliary clearance mechanism by
decreasing the ciliary beat frequency of bronchial epithelial cells [42].
The importance of the immune system and the inflammatory process in the pathogenesis of
COPD is becoming more apparent and NE is involved in several of these immune mechanisms.
NE can induce the expression of IL-8 in bronchial epithelial cells via TLR-4, subsequently
leading to neutrophil chemotaxis and increasing the inflammatory burden in the lung [43,
44]. NE also plays an important role in neutrophil migration both through the cleavage of fibrin
[45] and through the chemo-attractant properties of NE complexed with AAT [46]. The
immune function can be further affected by NE through the cleavage of CD4 and CD8
glycoproteins from the surface of T-cells, thus impairing the function of T-cells and contribu‐
ting to the inflammation seen in COPD [47]. Moreover, NE up-regulates the expression of TGF-
β1 in smooth airway muscle via the NFκB pathway and this may further contribute to the
airflow limitation seen in COPD [48]. Additionally, NE plays a role in the apoptosis seen in
the pathogenesis of emphysematous lesions. Accordingly NE has been demonstrated to induce
endothelial cell apoptosis [49], cytolysis of epithelial cells [42, 50] and cleaves the hydrophobic
phospholipid substrate phophatidylserine receptor on macrophages, which subsequently
impairs the ability of macrophages to clear apoptotic cells [51]. Collectively, these documented
reports demonstrate that NE is an integral enzyme involved in the pathogenesis of COPD and
emphysema and is a key target for therapeutic intervention.
COPD Clinical Perspectives72
2.1.2. Neutrophil derived proteinase 3
PR3 is the most abundant serine protease found in the neutrophil [52] and consequently more
PR3 than NE is released by the neutrophil during the phagocytosis process [53]. Similar to NE,
following activation of neutrophils by inflammatory cytokines, PR3 can be expressed on the
surface of neutrophils [52] and AAT potently inhibits PR3 in the circulation [2, 54]. In contrast
to AAT, SLPI has no effect upon PR3 and in fact PR3 is capable of degrading SLPI, thereby
enhancing the activities of NE and other serine proteases [55].
Animal studies have demonstrated that PR3 plays a role in the development of emphysema,
with studies showing that instillation of PR3 intra-tracheally leads to emphysematous lung
disease in hamsters [12]. PR3 is found in the sputum of both stable COPD patients and AAT
deficient individuals and increases at times of pulmonary exacerbations. Elevated PR3 levels
correlate with an increase in neutrophilic burden [56]. However, its elastolytic rate is relatively
low compared to NE, suggesting possibly a more minor role in the pathogenesis of emphysema
[57]. Studies have also shown that PR3 maintains pro-inflammatory properties, possessing the
ability to activate TNFα and IL-1β [58]. PR3 also has a strong effect on promoting the secretion
of mucus in the airways [59] and can lead to cell apoptosis in the lung [49, 60].
2.1.3. Cathepsin G and other cathepsins
Not all cathepsins are serine proteases and in fact include aspartate and cysteine proteases. In
this section we will discuss CathG, a serine protease related to NE and PR3 and briefly discuss
other cathepsins and their role in COPD. Of major importance, increased levels of cathepsins
have been demonstrated in BAL fluid of emphysema patients and therefore may play a role
in the pathogenesis of the condition [61].
CathG is a serine protease and is stored in the primary granules of neutrophils. Upon release,
activity of this protease is under the regulation of AAT and SLPI [19]. Increased levels of
cathepsins can be seen in the BAL fluid of patients with emphysema [61] but unlike NE and
PR3, in vivo animal studies have not demonstrated the same effect of CathG in inducing
emphysema [62]. Similar to the other serine proteases however, CathG can induce secretion
of mucus, hence adding to the airflow limitation and symptoms found in COPD [37]. More‐
over, CathG can impair T-cell function by cleaving trans-membrane glycoprotein co-receptors
on the cell surface in a similar fashion to NE [47].
Increased levels and activity of cathepsin L and cathepsin S have been shown in alveolar
macrophages of smokers [63, 64]. The expression of cathepsin S is induced by INF-γ and this
occurs in multiple cell types including smooth muscle cells. Subsequently, it has been shown
that over-expression of IFN-γ can increase the expression of cathepsin B, D, L and S [65].
Moreover, in murine investigational studies cysteine-protease inhibitors markedly reduced
the amount of airway inflammation and emphysema associated with over expression of
cathepsins B, H, K, L and S [66]. In addition, bacterial killing by the antimicrobial peptide LL-37
and by human beta-defensins is inhibited due to proteolytic degradation by cathepsin D [67]
and inactivation by the cysteine proteases cathepsins B, L, and S, respectively [68]. Although
there is far less evidence and reported studies on cathepsins they most likely play a contribu‐
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tory role to the pathogenesis of emphysema and should also be considered as possible
therapeutic targets in the future.
3. Matrix metalloproteases in COPD
MMPs are proteolytic enzymes which degrade components of the lung matrix, including
collagens and elastins. This occurs both under normal physiological conditions and during
abnormal pathological processes. MMPs are secreted as pro-enzymes and are activated by
proteolytic conversion and have a close relationship with cytokines and growth factors [69,
70]. MMPs have both collagenase and elastase activity and account for 50% of the elastolyt‐
ic  activity  of  BAL fluid in  smokers  [71].  Indeed,  MMPs account  for  the  majority  of  the
elastolytic activity of macrophages in COPD patients [72] and are counteracted by tissue
inhibitors of matrix metalloproteases known as TIMPs. Additionally,  MMPs do not only
demonstrate degrading properties but also are pro-inflammatory in nature, with liberated
matrix fragments possessing pro-inflammatory and monocytic chemotactic properties [73,
74].
3.1. Macrophage derived matrix metalloprotease-12
MMP-12, also known as macrophage-metalloelastase, is perhaps the most studied and best
understood MMP in emphysema and COPD and numerous animal models have demonstrated
its role in lung disease. It is involved directly in matrix degradation and is also a pro-inflam‐
matory peptide. A recombinant form of human MMP-12 has been used to demonstrate the
direct role that MMP-12 plays in the inflammatory process in the airways of mice [75]. This
recombinant form of MMP-12 caused an increase in neutrophils and in macrophages accom‐
panied by increased levels of pro-inflammatory cytokines and MMPs. Human studies have
reported that the number of alveolar macrophages in BAL fluid expressing MMP-12 was
higher in COPD patients than in controls [76]. MMP-12 can also be produced by bronchial
epithelial cells [77] and is expressed by airway smooth muscle [78]. Cigarette smoke has been
repeatedly shown to up-regulate both the release and production of MMP-12 [79]. How this
occurs is complex in nature and likely through several mechanisms. For example, upon
exposure to smoke, proteins including plasminogen and prothrombin are released into the
alveolar space where they are converted to plasmin and thrombin, both of which are serine
proteases. Their action upon proteinase activated receptor-1 (PAR-1) subsequently leads to the
secretion and activation of MMP-12 [80, 81]. A second mechanism by which smoke may
activate MMP-12 has been shown in mice where it was shown to up-regulate GM-CSF
production which in turn controls MMP-12 release [82]. Moreover, the gene expression of
MMP-12 in epithelial cells is affected by reactive oxygen species [83] and in murine studies a
direct link between MMP-12 and cigarette smoke induced airway inflammation has been
demonstrated [84-86]. Moreover, in MMP-12 knockout mice a marked reduction in monocyte
recruitment and in IL-13 and IFN-γ induced emphysema has been demonstrated, implicating
the importance of MMP-12 in the inflammatory response seen in COPD [65, 66]. How MMP-12
exerts this inflammatory effect is multifactorial. One reported mechanism involves the pro-
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inflammatory action of MMP-12 through the release and activation of TNFα [87]. Secondly,
MMP-12 has also been shown to possess the ability to induce the production and release of
IL-8 via the EGFR pathway in epithelial cells [88]. The importance of MMP-12 in inducing
airway inflammation is further supported by the use of MMP-12 inhibitors which were shown
to ameliorate emphysema in experimental animals [89] and to lower both the concentration of
immune cells in BAL fluid, and to affect inflammation [90]. MMP-12 also impacts upon the
activity of other proteases, especially neutrophil derived enzymes including NE, PR3 and
cathepsins, and can degrade AAT hence up-regulating the activity of these serine proteases
[91].
Despite convincing evidence provided by experimental models and compelling data showing
an association between MMP-12 and emphysema, the data from human studies is conflicting
and not as clear cut. A number of studies have suggested increased expression of MMP-12 in
alveolar macrophages and increased MMP-12 protein in sputum of COPD individuals
compared to healthy controls [76, 92, 93] while others have shown no difference [94-96]. Thus
further studies on MMP-12 are essential to confirm the role of this matrix metalloprotease in
inflammation and tissues destruction associated with COPD.
3.2. Neutrophil released matrix metalloprotease-9
The next most studied and understood MMP in COPD is MMP-9. Also known as gelatinase-
B and similarly to other matrix metalloproteases MMP-9 has multiple substrates includ‐
ing collagens IV, V, VII, X and XI as well as elastin, gelatin, pro-MMP9 and pro-MMP13.
MMP-9 is  secreted by bronchial  epithelial  cells,  mast  cells,  neutrophils,  eosinophils  and
alveolar macrophages in response to TGFβ, IL-13 and IL-8 [79].
Increased levels of MMP-9 have been demonstrated in smokers with and without airflow
obstruction [97, 98] and a correlation between the levels of MMP-9 in sputum and the extent
of airflow obstruction and symptoms in COPD has been reported [99]. There are also increased
levels of MMP-9 in AAT deficient individuals, where levels correlated with clinical parameters
including FEV1, DLCO, lung density and exacerbation frequency [98, 100]. Elevated levels of
MMP-9 in COPD individuals have been demonstrated to correlate to the number of neutro‐
phils, implicating MMP-9 in the inflammatory burden in COPD [98, 101]. Moreover, poly‐
morphism in the promoter region of the human MMP-9 gene has been shown associated with
emphysema in 2 separate Japanese cohorts [102, 103] and with COPD in a Chinese population
[104].
In support of a role for the involvement of MMP-9 in COPD, ex vivo studies have shown that
alveolar macrophages from BAL fluid in emphysema patients demonstrate increased expres‐
sion of MMP-9 and MMP-1 compared to control subjects [95]. This is also true for smokers
with and without COPD where there is increased expression of MMP-9 on alveolar macro‐
phages compared to healthy controls [105, 106]. In a study comparing COPD patients to
smokers with no evidence of airflow obstruction, alveolar macrophages from COPD individ‐
uals released increased levels of MMP-9 and in vitro the stimulation of these cells by IL-1β,
lipopolysaccharides (LPS) and cigarette smoke increased the secretion of MMP-9 [106].
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Consequently, emphysematous lung tissue has been shown to contain higher levels of MMP-9
compared to disease free tissue [107, 108].
Other studies of interest that provide evidence for the involvement of MMP-9 in the inflam‐
matory process associated with COPD include data that demonstrate that MMP-9 possesses
levels of TACE (TNFα converting enzyme) like activity and mediates acute cigarette smoke-
induced inflammation via TNFα release [87]. MMP-9 may also be involved in the link between
destruction of alveolar tissue and fibrotic proliferation observed in emphysema, potentially
mediated by proteolytic cleavage of latent TGF-binding-protein-1 with subsequent release of
TGFβ-1, possibly linking elastolysis and fibrosis [109, 110]. Interestingly, MMP-9 may be
activated by NE via cleavage of pro-MMP-9 to active MMP-9 [111]. Moreover, NE has been
shown to degrade TIMP-1 thereby leading to enhanced MMP-9 activity [112], implicating both
NE and MMP-9 in the pathogenesis of COPD. Finally, a role for MMP-9 in mucus hyper-
secretion in COPD patients has been suggested, as MMP-9 activates epidermal growth factor
which in turn increases the expression of MUC5AC production hence leading to increased
mucus secretion [113, 114].
3.3. Matrix metalloprotease-1 and other matrix-metalloproteases
MMP-1, also known as interstitial collagenase-1, is active against multiple collagens including
collagen I, II, III and VII, gelatin and pro-MMP9 and over-expression in mice has been
associated with development of emphysema [115]. Loss of collagen type II leads to an increase
in lung compliance and hence the development of emphysema [116]. In humans, BAL fluid
from emphysema patients has increased MMP-1 expression compared to healthy controls
[117] and increased expression of MMP1 was reported in the lungs of patients with emphysema
[94]. This expression was localised to type II epithelial cells but not alveolar macrophages.
MMP-1 is also expressed by airway smooth muscle [118] and the production of MMP-1 is
driven by the MAPK pathway and also by hydrogen peroxide, an important pathogenic
component of cigarette smoke [119]. In mouse models, MMP-1 has been shown to contribute
to alveolar destruction leading to emphysema development [120, 121]. Similar to MMP-9,
MMP-1 also possesses levels of TACE like activity which may contribute to the inflammation
seen in COPD [87].
MMP-2 which is also known as gelatinase-A has activity against collagens I-V, VII, X, XI and
XIV as well as elastin, fibronectin and gelatin. Increased levels of MMP-2 have been demon‐
strated in COPD lungs [107, 108] and also in experimental mice exposed to cigarette smoke
[122]. Interestingly, in guinea pigs exposed to wood-smoke increased expression of MMP2 was
recorded, possibly providing an insight into the pathogenesis of emphysema in individuals
not exposed to cigarette smoke [123]. Moreover, increased levels of both MMP-8 and MMP-10
are seen in sputum of COPD patients and have been shown to correlate with airflow obstruc‐
tion [97, 124], with increased levels of MMP-8 recorded at the time of acute pulmonary
exacerbation [125]. Finally, MMP-12 is up-regulated in mice exposed to cigarette smoke [126]
and elevated levels of MMP-13 are seen in individuals with emphysema [127].
Collectively, this information on MMPs contributes to the protease/antiprotease theory in
COPD pathogenesis and provides targets that may be investigated when developing future
COPD Clinical Perspectives76
therapeutic strategies. MMPs play a mixed role in COPD and are involved in the proteolytic
destruction of lung tissue and possess a close relationship to neutrophil derived serine
proteases. These latter processes are intertwined and hence targeting certain elements of
protease induced inflammatory processes may provide encouraging and exciting therapeutic
options.
4. Approaches to treatment
Current therapies for the treatment of COPD are similar between the non-genetically inherited
form of the lung disease and COPD as a result of AAT deficiency, and are in line with the
American Thoracic Society/European Respiratory Society published guidelines [128]. Of
particular importance is the cessation of smoking for individuals diagnosed with the disorder,
as smoking aggravates the condition and is a predominant prognostic factor for the outcome
of COPD patients. Therapeutic strategies aimed at the protease-antiprotease imbalance can be
expected to have the greatest effect on lung disease associated with COPD and AAT deficiency.
Ensuing sections will focus on AAT augmentation therapy in both intravenous and aerosolized
forms, transgenic and recombinant forms of AAT and administration of either natural (elafin
and SLPI) or synthetic (Sivelestat) antiproteases for treatment of COPD.
4.1. AAT replacement therapy
The importance of the protease: antiprotease balance is evident by the development of
emphysema in AAT deficient individuals due to unopposed NE activity, of which AAT is the
major inhibitor. Indeed the most logical approach to treatment is the reestablishment of
physiological levels of AAT. The minimum level of AAT required to protect the lung from
protease mediated damage was set as 11µmol/L (or 80mg/dL), and this has been referred to as
the “protective” threshold level [129]. This value is based on the levels of AAT recorded in
non-smoking individuals with the PiSZ phenotype, which is not thought to confer an increased
risk of developing lung disease. Intravenous infusion of human plasma derived AAT, also
referred to as AAT augmentation therapy, provides a method of maintaining this protective
threshold and thus delays the progression of emphysema (Table 1). In 1981, researchers
developed a method for partially purifying AAT from pooled human plasma and with the
knowledge that the serum half-life of AAT is 5.4 days [130], devised an infusion schedule that
allowed once weekly administration of purified AAT to AAT deficient individuals. Following
such infusions the results of this study demonstrated that significant amounts of AAT, with
full anti-NE capacity, diffused to the lower respiratory tract. Consequently, infusion of purified
human plasma AAT at a dose of 60mg per kilogram of body weight per week, a dose that was
sufficient to maintain serum levels ≥ 11µmol/ L, was FDA-approved and is now widely used
in Europe and North America in treatment of AAT deficient individuals [131]. The first
available preparations of AAT included pooled human plasma AAT prepared by pasteurisa‐
tion (Prolastin, Bayer, West Haven, CT, USA). In turn, more recent studies examined the
biochemical effectiveness of AAT purified by solvent detergent and nano-filtration method‐
ology (Aralast, Baxter, Westlake Village, CA, USA) [132] and a third preparation (Zemaira,
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CSL Behring, PA USA) has received US FDA approval [133]. Currently there are six FDA
approved AAT preparations available in the USA. The clinical effects of infused AAT therapy
documented to date consist of patient outcome measures including the rate of FEV1 decline
[134, 135], the level of desmosine as a biomarker of elastin degradation [136, 137], the incidence
of acute exacerbations [138], frequency of lung infections [139] and the change in lung density
[140] calculated by CT scanning [141]. Nevertheless, though studies have demonstrated that
infusion of AAT is safe and well tolerated [142], there remains considerable debate over the
clinical benefits and the cost-effectiveness of the treatment [134, 143, 144].
Study Type AAT Infusion Reference Patient outcome
Observational Weekly (Ma et al. 2013) Reduced elastin degradation in treatedgroup
Observational Weekly (Tonelli et al. 2009) Slower rate of decline in FEV1% predictedin augmentation group
Randomized Weekly (Dirksen et al. 2009) Attenuated loss of lung tissue in treatedcohort measured by CT lung density
Observational Weekly (Wencker et al. 2001) Reduced rate of FEV1 decline postaugmentation therapy
Descriptive Weekly (Gottlieb et al. 2000) Elastin degradation was not reduced
Observational 56% weekly & 26%biweekly (Lieberman 2000) Decline in number of infections per year
Randomized controlled 4-weekly (Dirksen et al. 2009) Reduced loss of lung tissue by CTdensitometry with augmentation
Observational parallel
controls
51% weekly & 25%
biweekly (group 1998)
Slowed decline in FEV1 of 27ml/year in
treated group
Observational parallel
controls Weekly (Seersholm et al. 1997)
Reduced rate of decline of FEV1 in treated
group of 21ml/year.
Table 1. Treatment of patients with AAT deficiency with augmentation therapy
The biochemical efficacy of AAT augmentation therapy has been examined in a number of
studies and in 1987 Wewers and colleagues demonstrated that a weekly dosage of 60mg/kg
not only restored AAT levels in serum and BAL fluid but also increased anti-NE capacity from
a baseline value of 5.4 ± 0.1µM in the serum to 13.3 ± 0.1µM [142]. Indeed, additional studies
have focused on the impact of augmentation therapy on the inflammatory environment of the
lung. For example, AAT deficiency is characterised by increased neutrophil numbers and thus
increased sputum and BAL fluid levels of NE [145]. This burden of neutrophils in the lung as
a result of excessive trafficking is attributed to chemotactic agents such as IL-8 and LTB4 and
significantly higher levels of these chemo-attractants have been recorded in sputum from
individuals with AAT deficiency compared to COPD patients. To understand this further, an
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in vitro study discovered increased release of LTB4 from AAT deficient alveolar macrophages
as a result of unopposed NE activity. Of relevance, the addition of exogenous AAT reduced
the amount of LTB4 being released by macrophages in response to NE [146]. In confirmation
of this latter study, Stockley et al demonstrated that sputum samples from AAT deficient
individuals on day one post infusion of AAT augmentation therapy possessed reduced NE
activity and a dramatic attenuation of LTB4 concentration from a level of 13.46nM to 8.62nM
[147]. Moreover, the anti-inflammatory effects of AAT augmentation therapy were confirmed
as decreased concentrations of IL-8, and the chemotactic activity mediated by this chemokine,
were reduced to normal levels in AAT deficient individuals post treatment. [148, 149]
One of the first studies to examine the effect of AAT augmentation therapy compared the
ΔFEV1 of 97 ex-smokers from a Danish AAT deficient registry to a German group of 198
patients treated with weekly infusions of AAT (60mg/kg) for at least one year. Overall, the
ΔFEV1 in the treated group was significantly lower than in the untreated group, with annual
declines of 53 mL yr-1 and 75 mL yr-1, respectively (p=0.02). However, there was no beneficial
effect of augmentation therapy in 103 patients with an initial FEV1 ≤ 30 or in the 25 patients
with an FEV1 > 65% [134]. In 1998, one of the largest observational studies (n=1129) centred on
the NHLBI Registry for individuals with severe AAT deficiency [150] was carried out.
Although no overall difference in FEV1 decline was recorded between the augmentation-
therapy treated and untreated groups, in a subgroup with FEV1 between 39-45% predicted
there was a significant difference of -27ml/year between treated and untreated. This study also
suggested that survival was enhanced in individuals receiving augmentation therapy. The risk
ratio for death in augmentation therapy recipients was 0.64, significantly lower than non-
recipients (P=0.02) and the risk ratio for individuals receiving augmentation therapy with stage
II COPD was 0.21 (P<0.001). The possibility that these differences may have been due to other
factors, such as the socioeconomic status of enrolled patients could not be ruled out and this
latter point is a potential limitation of this study. In a subsequent randomised study of 164
AAT deficient individuals enrolled in the Alpha-1 foundation DNA and tissue bank, when
adjusted by age at baseline, sex, smoking status, baseline FEV1 % of predicted, a slower rate of
decline in FEV1% predicted was observed in the augmentation group (10.6±21.4 ml/year) in
comparison to the non-augmented group (36.96±12.1ml/year). The authors of this study
concluded that augmentation therapy was effective in subjects with AAT deficiency, favouring
ex-smoker subjects with an FEV1 below 50% of predicted [151].
Results from studies measuring changes in urine desmosine levels, a marker of elastin
breakdown, in response to AAT augmentation therapy have been mixed. One study of two
AAT deficient patients observed a 35% reduction in urine desmosine levels after monthly doses
of 260mg/kg AAT [152]. In contrast, a larger study by Gottelieb et al showed no change in the
level of elastin breakdown after eight weeks of augmentation therapy (P=0.85). Although this
latter study recruited only twelve AAT deficient individuals, the authors suggested that elastin
degradation at this point in the disease was possibly NE independent [137]. In a recent study
desmosine levels were assessed in plasma, BAL fluid and urine in a cohort of AAT deficient
patients receiving AAT augmentation therapy. A 13.9% reduction in plasma and 37% reduc‐
tion in BAL fluid desmosine levels were observed 12 weeks after receiving IV augmentation
Antiproteases as Therapeutics to Target Inflammation in Chronic Obstructive Pulmonary Disease
http://dx.doi.org/10.5772/57455
79
therapy compared to baseline levels prior to treatment [153]. The study showed that augmen‐
tation therapy maintained the ability to inhibit NE and to reduce degradation of elastin both
systemically and in the lungs, however the findings suggested that the dose of AAT was not
sufficient to reduce elastin degradation to that of control levels of healthy individuals. There
is a relatively limited body of clinical evidence supporting the benefits of 60mg/kg dosage,
with some even questioning the recommendation of this dose of AAT to AAT deficient patients
[154]. The concentration of 60mg/kg aims to increase AAT levels to values above that of the
protective threshold (11µM) yet levels are still below that of serum AAT concentration
observed in non-AAT deficient individuals (20-53µM) [155]. To address this issue Campos et
al assessed the safety and efficacy of an increased 120mg/kg weekly dose of AAT in 30 adults
with AAT deficiency in a multicentre, randomised, double-blind crossover study. A weekly
dose of 120mg/kg resulted in a serum concentration of 27.7µM four weeks after treatment, well
within the healthy control range, compared to 17.3µM at the same time period for the group
receiving 60mg/kg. Concurrently, this increased dosage was considered to be safe and well-
tolerated, however further investigation is warranted due to the relatively small cohort size
and the lack of analysis of clinical parameters such as FEV1 and CT densitometry [156].
Currently desmosine is the only clinical biomarker for assessment of lung tissue destruction,
however it is limited by lack of specificity and may be influenced by diet and renal function
which may in part provide an explanation for the lack of association between desmosine levels
in the urine and FEV1 [157-159]. Current research is aimed at identifying cost effective yet stable
novel biomarkers that are central to the pathophysiological process, which can act as a
predictor of disease progression and are sensitive to therapeutic intervention [160, 161]. In this
regard, a novel potential biomarker has been recently reported specific to cleavage of fibrino‐
gen and related to NE in the lungs [136]. The fibrinogen cleavage product Aα-Val360 was
measured in plasma from subjects recruited in the EXACTLE trial and the levels of this product
were decreased in subjects receiving AAT replacement therapy while remaining unchanged
in the placebo group.
Determining exacerbation rates in patients receiving therapy is an additional parameter that
is employed to determine the efficacy of AAT replacement therapy. In a web based question‐
naire prepared by Lieberman and colleagues, key questions addressed issues such as frequen‐
cy of respiratory infections pre- and post-AAT augmentation therapy [139]. Out of eighty nine
individuals who had received augmentation therapy for more than one year, seventy four felt
that the treatment was of benefit, with almost half accrediting the benefits to a reduction in the
number of infectious exacerbations from approximately five down to one per year (P<0.001).
CT lung density measurements are currently considered to be a more sensitive outcome to
measure the impact of AAT replacement therapy. The first of these studies was a double blind
trial with 26 Danish and 30 Dutch ex-smokers, randomized to either AAT (250 mg/kg) or
albumin (625 mg/kg) infusions at 4 week intervals for at least 3 years [140]. Using self-
administered spirometry, no difference was found in FEV1 decline between treatment and
placebo. Conversely, upon analysis of CT scans (slices 5 cm below carina), a trend towards a
slower rate in loss of lung density was observed in augmentation receiving patients with
measurements of 2.6 ± 0.41 g/L/yr for placebo as compared with 1.5 ± 0.41 g/L/yr for AAT
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infusion, however the reported differences were shown to be non-significant (P=0.07), possibly
due to the inadequate study size. Following this, in 2009, Dirksen et al. carried out a rando‐
mised, double-blind, placebo-controlled, parallel-group study conducted at three European
centres (Copenhagen (Denmark), Birmingham (UK), and Malmö (Sweden)) known as the
EXACTLE trial. CT scans were performed at baseline and at 12 and 24 months and the
difference in the decline of lung density between treated and placebo groups suggested a trend
towards a beneficial treatment effect, with P values for treatment difference ranging from 0.049
to a non-significant value of 0.084 depending on the outcome algorithm chosen. In 2010,
Stockley and colleagues analysed the combined outcome measures of the EXACTLE and
Danish-Dutch trial and concluded that augmentation therapy conferred a significant decline
in the rate of CT densitometric loss but not in FEV1 decline [162].
A number of studies have addressed the potential clinical use of AAT augmentation therapy
in treatment of disorders outside the context of AAT deficiency, including transplant rejection,
type1 diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, viral infection and
cystic fibrosis [163]. In light of this, there is a need that goes beyond that afforded by purified
human plasma and thus transgenic and recombinant AAT have been considered.
4.2. Recombinant and transgenic AAT
Despite the accumulation of encouraging data supporting the use of AAT augmentation
therapy, significant questions remain regarding the cost-effectiveness of this intravenous
strategy for treatment of AAT deficient related COPD, which is estimated to cost the US
$100,000 per patient per year worldwide [143]. Such deliberation has prompted the develop‐
ment of new strategies, including the use of recombinant and transgenic protein to boost the
natural antiprotease screen. A variety of systems have been employed to produce humanized
recombinant AAT including plants, yeast fungi, animals, insect cells, bacteria and mammalian
cells. One of the approaches involved expression of recombinant AAT in E. coli, but AAT
produced via this system lacked glycosylation and consequently exhibited a short half-life
within the circulation. To address this issue the presence of a single thiol residue at the surface
of AAT was exploited by researchers, who conjugated maleimido-polyethylene glycol to the
thiol group. Results revealed that site-specific conjugation with polyethylene glycol at Cys232
of nonglycosylated recombinant human AAT gave rise to active inhibitor with prolonged in
vivo stability [164]. An alternative approach included production of a secreted fully functional
AAT by the yeast Saccharomyces cerevisiae [165]. This secreted protein had high mannose-type
glycosylation [166], which was thought to give rise to an immune response in humans because
of non-human glycan residues, an adverse effect shared by active recombinant AAT protein
expressed in the insect cell baculovirus expression vector system [167]. In an attempt to over-
come the issue of glycosylation, a method of hyper glycosylation of the protein was introduced.
This was achieved by adding terminal sialic acids to the existing glycans on the human AAT
molecule. Such modification conferred increased protein half-life while maintaining the anti-
NE capacity of the protein when injected into a mouse model [168]. In a further attempt to
prepare fully glycosylated human AAT, Blanchard et al employed a human neuronal cell line
(AGE1.HN®) to produce a recombinant AAT protein which retained biological activity and
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displayed a similar glycosylation patterns to native AAT [169]. Moreover, the recombinant
AAT protein was biologically active and maintained anti-elastase activity and anti-inflamma‐
tory capacity, including modulation of TNFα production in neutrophils and monocytes [169].
In vitro testing of this protein revealed that the inhibitory effect of the recombinant AAT was
comparable to that of Prolastin, however this has yet to be confirmed in vivo. More recently,
AAT has been successfully produced and purified from the human PER.C6 cell line. The
resultant protein shares the same primary, secondary and tertiary structures and N-linked
glycosylation sites as AAT derived from human plasma and exhibits equivalent anti-NE
capacity [170, 171]. While these studies strengthen the argument for the therapeutic use of
recombinantly produced AAT, issues still remain with regards to the safety and efficacy of
protein produced in this manner.
Subsequently, it was envisaged that sources of recombinant AAT from transgenic animals
might overcome this posttranslational glycosylation challenge and fulfil the demand for mass
production of AAT. To this end rabbits [172], mice [173] and sheep transgenic for a fusion of
the ovine beta-lactoglobulin gene promoter to the human AAT genomic sequences were
generated [174]. Human AAT purified from the milk of these animals appeared to be fully N-
glycosylated and biologically active. While the use of transgenic sheep certainly tackled the
issue of cost effectiveness, 5,000kg of AAT could be produced in one year, unfortunately
however, a trial of inhaled AAT derived from sheep milk proved disappointing and observa‐
tions of a systemic antibody response in recipients to residual native sheep AAT and alpha-1
antichymotrypsin were observed [175]. Thus it is clear that transgenic preparations of AAT
will only be of therapeutic value if they are of high purity in order to avoid immunogenicity.
While enhancing production of AAT seems promising from a cost and mass production point
of view, significant challenges remain for the development of recombinant and transgenic AAT
and they cannot compete with the current source of AAT from pooled human plasma for safety
and efficacy in the treatment of AAT deficiency.
4.3. Aerosolized AAT augmentation therapy
Interest in the administration of AAT in aerosolized form has increased in recent years due to
the advantageous properties provided such as a direct route to the lungs, avoidance of systemic
deliver and a reduction in costs. Aerosolization of AAT has been shown to increase AAT levels
and to restore anti-NE capacity in lung epithelium lining fluid of both COPD and cystic fibrosis
individuals [176]. AAT administered in aerosolized form was found to positively impact upon
neutrophil mediated killing of Pseudomonas [177], possibly by preventing cleavage of neutro‐
phil complement receptors by serine proteases, a previously reported adverse effect of NE
[178] or by preventing cleavage of CXC chemokine receptor 1 (CXCR1) [179]. In addition, the
presence of increased AAT in serum post aerosolization supports the hypothesis that aug‐
mented AAT is capable of diffusing across the pulmonary interstitium after administration
[180] and affords anti-NE protection to the interstitial compartment [176]. Measurements of
the rate of transfer of AAT from the lung and of the rate of appearance of AAT in plasma
resulted in a calculated permeability of the alveolar-capillary membrane to AAT of 3.49-6.39
X 10-10 cm/s. In a canine model, levels of AAT rose to a maximum value at 48 hours after
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administration, remained elevated from 48-72 hours, and then declined slowly by 144 hours
after administration [180]. Comparable results were reported by Hubbard et al. who evaluated
aerosol administration of recombinant AAT to COPD individuals with AAT deficiency. Post
aerosolization of single doses of 10-200mg of AAT, AAT anti- NE defences in ELF were
augmented and aerosolized AAT was detectable in serum indicating that recombinant AAT
was capable of gaining access to lung interstitium [176].
Further support for the use of aerosolized AAT in treatment of COPD was provided by Griese
and colleagues who examined the effect of four weeks of plasma purified AAT inhalation on
lung function, protease–antiprotease balance and airway inflammation in patients with cystic
fibrosis [181]. The authors reported an increased concentration of aerosolized AAT accumu‐
lation in the airways. Post treatment, levels of NE activity, numbers of infiltrating neutrophils,
pro-inflammatory cytokines levels and the numbers of bacteria (P. aeruginosa) were reduced
culminating in a marked reduction in airway inflammation. In a second study by this research
group, the authors documented that the inability of neutrophils to eradicate Pseudomonas
infection despite the abundance of neutrophils in the cystic fibrosis lung was due to cleavage
of CXCR1 from the neutrophil. In vivo administration of aerosolized AAT was shown to restore
CXCR1 expression and improve the killing capacity of neutrophils as assessed by sputum
levels of P. aeruginosa, thus supporting the beneficial effects of aerosolized AAT therapy [179].
In a further study employing a mouse model of smoke induced emphysema, inhaled AAT
resulted in reductions in airspace enlargement of up to 73%. The results of this investigation
indicated that delivery of AAT directly to the lung can prevent NE mediated tissue damage.
Moreover, further evidence of the ability of aerosolised AAT to directly protect the lung tissue
from proteolytic breakdown was demonstrated as aerosolised AAT abrogated NE-induced
expression of cathepsin B and MMP-2 in BAL fluid, thus indirectly protecting key anti-
inflammatory and antimicrobial peptides including SLPI and lactoferrin from cathepsin
mediated proteolysis within the milieu of the COPD lung [36]. In terms of clinical efficacy of
aerosolised AAT, a phase III trial of inhaled Kamada AAT is currently on-going with results
on outcome measures including safety and efficacy, exacerbation frequency and progression
of emphysema to be released presently. The outcome of this study will be pivotal to shaping
the future development of aerosolised AAT augmentation therapy (NCT01217671).
4.4. Naturally occurring antiproteases elafin and SLPI as therapies for COPD
A number of studies have generated data to support the use of naturally occurring antipro‐
teases, other than AAT, as potential anti-inflammatory therapies to modulate the high level of
inflammatory within the lungs of COPD patients. Within the literature reports suggest that
serine protease inhibitors may potentially be used as a treatment option for COPD. One such
antiprotease is elafin, a small cationic protein (6kDa) which is a member of the chelonianin
family. Throughout the literature it is often referred to as skin derived anti-leukoprotease
(SKALP) due to its first identification in psoriatic epidermis [182]. More recently however, it
has been shown to be produced and released by epidermal keratinocytes [183], lung derived
epithelia [184], T-cells [185], macrophages [186] and also neutrophils [187].
Antiproteases as Therapeutics to Target Inflammation in Chronic Obstructive Pulmonary Disease
http://dx.doi.org/10.5772/57455
83
Elafin is a subunit derived from the precursor molecule trappin-2 which has a molecular
weight of 12.3 kDa [188]. The conversion of trappin-2 into elafin can occur by cleavage by
several proteases including cathepsin L, cathepsin K, plasmin, trypsin but the most efficient
protease at releasing elafin is tryptase [189]. The mature form of trappin-2 consists of two
domains; the first domain is unique to only trappin-2, the N-terminal cementoin domain. This
domain aids as a transglutaminase substrate which allows trappin-2 to interact and bind to
extracellular matrix proteins such as fibronectin, collagen IV, fibrinogen, laminin V, vitronec‐
tin, thus prolonging its presence within in the lung [188]. The second domain, which is present
in both trappin-2 and elafin, is the whey acidic protein (WAP) domain. The WAP domain
provides antiprotease activity with specificity against NE [18] and PR3 [17], two key proteases
that play a role in the lung pathophysiology associated with COPD [56, 190].
Several studies have demonstrated that elafin is produced under inflammatory conditions
suggesting it to be an acute phase reactant [191]. Interestingly, NE can impact on elafin
expression and it has been demonstrated that exposing human alveolar epithelial cells to NE
can result in increased protein expression and secretion of elafin [192]. Additional studies have
demonstrated that pro-inflammatory mediators such as TNFα and IL-1β increase elafin
expression in lung derived cell lines, indicating that in response to cytokine induced inflam‐
mation, epithelial cells can increase their antiprotease shield [191]. This induced increase in
elafin expression is not limited to only host derived inflammatory mediators as it has been
shown that bacterial LPS can increase elafin expression in murine airways [193] and in
macrophages from transgenic mice expressing human elafin [194].
The immuno-modulatory impact of elafin on inflammation has been established in a number
of studies and animal models. For example, Vachon and colleagues utilised a murine model
and following intranasal administration of LPS, pre-treatment with recombinant human elafin
was shown to diminish neutrophil infiltration into the airways [195]. In the same study elafin
was shown to reduce gelatinase activity, macrophage inflammatory protein-2 (MIP-2),
keratinocyte chemoattractant and significantly reduced mRNA levels of three members of the
IL-1 ligand family [195]. Conversely, in an earlier study involving a transgenic murine model
expressing human trappin-2, an increase in neutrophil recruitment to the lungs of LPS
challenged mice was observed [193]. The discrepancy between these two latter studies could
in part be due to differences in the mode of elafin administration and the murine models
employed. Of interest, the positive impact of elafin on COPD related complications such as
pulmonary hypertension has been reported [196]. Moreover, in a hypoxia associated pulmo‐
nary hypertension murine model the protease activity, muscularization of pulmonary arteries
and right ventricular pressure were reduced in transgenic mice that over expressed elafin
[197]. Indeed, both elafin and its precursor molecule trappin-2 have anti-inflammatory
properties, as evident by the inactivation of key inflammatory signalling pathways and
immune cell activity associated with COPD pathogenesis. In a study using a human myelo‐
monocytic cell line, elafin was shown to exert its anti-inflammatory effect intracellularly [198].
The mode of action involved direct impact on the ubiquitin-proteasome pathway, delaying
turnover of polyubiquitinated proteins thus affecting NFκB activation and the AP-1 pathway
leading to reduced MCP-1 expression in response to LPS [198]. Moreover, in transfection
COPD Clinical Perspectives84
studies it was demonstrated that the impact of elafin on chemokine production was cell specific
[199]. Results demonstrated that elafin reduced TNFα secretion by human macrophages and
IL-8 release by human umbilical cord endothelial cells (HUVECs) in response to TNFα, LPS
and oxidized LDL, through modulation of NFκB signalling. In contrast, in the same study
transfecting an alveolar epithelial cell line with elafin had no significant effect on LPS induced
IL-8 production [199].
In addition to possessing antiprotease and anti-inflammatory properties, elafin also demon‐
strates anti-microbial properties which may prove beneficial in the treatment of infective
exacerbations in COPD patients. In a study carried out by Simpson et al., the anti-bacterial
capability of elafin was evaluated and the results demonstrated that elafin maintained
bactericidal effect against both P. aeruginosa and S. aureus [200]. This effect could in part be due
to the cationic charge of elafin which may destabilize bacterial membranes similar to classical
antimicrobial proteins [201]. Moreover, a study by Baranger et al., demonstrated that trappin-2
had antibacterial properties against other clinically important bacteria including Klebsiella
pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis [202].
Furthermore, this study highlighted the novel anti-fungal effect of trappin-2 against Aspergillus
fumigatus, with the outcome of this study demonstrating the anti-microbial properties of
trappin-2 to be independent of its antiprotease property. Aside from direct activity against
microbes, trappin-2 in turn has been shown to enhance the clearance of P. aeruginosa from the
lungs of infected mice [203], an effect mediated via opsonisation of bacteria with trappin-2 for
more efficient CD14-dependent clearance by macrophages [197]. In additional studies it has
been shown that elafin can modulate inflammation associated with LPS, through inhibition of
AP-1 and NFκB activation [198], possibly by direct interaction with this microbial inflamma‐
tory mediatory [204].
These innate attributes of elafin make it an ideal candidate for a replacement therapy in
treatment of inflammatory lung diseases such as COPD which is associated with excess
protease burden and/or infection. However caution must be exercised, as like many other
endogenous protease inhibitors, elafin is susceptible to inactivation by neutrophil-derived
oxidants resulting in loss of its antiprotease activity [205]. Moreover, elafin can be cleaved by
NE [206], which is present in high concentrations in the COPD lung [207] and cleavage can
result in diminished ability of elafin to bind LPS and its capacity to be immobilized by
transglutamination [206]. A similar observation was made in regard to the P. aeruginosa derived
proteases pseudolysin and aeruginolysin which can cleave elafin thereby negatively impacting
on its biological functions [208]. Collectively, these findings suggest that within an environ‐
ment of high protease burden, as found in the COPD lung, this could have a negative impact
upon the clinical efficacy of elafin.
An additional native antiprotease that has been well documented for its potential as a therapy
for COPD is human SLPI, which was originally identified in parotid secretions [20]. Being a
member of the antileukoprotease family, SLPI shares 40% homology with elafin. A number of
cell types have been documented to produce SLPI including macrophages [186], monocytes,
neutrophils [187] and lung epithelial cells [209]. It is well accepted that SLPI is a potent inhibitor
of an array of serine proteases including NE, cathepsin G, trypsin and chymotrypsin. Similar
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to elafin, SLPI expression levels are increased post inflammatory mediator exposure; for
example TNFα and IL-1β treatment of lung epithelial cells [191]. Other host derived inflam‐
matory proteins including proteases from neutrophils (e.g. NE and defensins [184] ) can
increase and induce SLPI expression in bronchial epithelial cells. In more recent studies, aside
from host derived inflammatory mediators, bacteria have also been shown to induced SLPI
expression in macrophages by a TLR2-dependent but MyD88-independent signalling pathway
[210]. Additionally, bacterial products such as LPS can increase SLPI expression in macro‐
phages and neutrophils [211], suggesting that SLPI functions as an acute phase reactant.
SLPI exhibits an array of anti-inflammatory properties including inhibition of monocyte
production of MMPs [212, 213] which play an important pathophysiological role in tissue
remodelling and are observed to be in high abundance in COPD [95, 107, 214]. The range of
anti-inflammatory properties of SLPI includes inhibition of nitric oxide and TNFα production
in macrophages in response to LPS [215] and inhibition of IFN-γ induced cathepsin S expres‐
sion in macrophages [216]. In monocytes it has been demonstrated that SLPI can cross the
plasma membrane and enter the cell cytoplasm and nucleus [217]. Localization to these cell
compartments facilitates the ability of SLPI to inhibit degradation of key proteins that activate
NFκB and to competitively compete with p65 binding to NFκB consensus sequences thereby
preventing NFκB binding to promoter regions of inflammatory genes [217]. In a more recent
study involving neutrophils from COPD patients, the intracellular inhibitory activity of SLPI
was further expanded as it was shown that SLPI modulated calcium flux and inositol 1,4,5-
triphosphate generation thereby reducing cell migration [218] Additionally, SLPI possesses
anti-microbial capabilities against P. aeruginosa, S. aureus, S. epidermidis, E. coli and S. aureus
[219, 220]. SLPI’s antifungal properties have been observed against A. fumigatus and Candida
albicans [221] and in this latter study SLPIs fungicidal and fungistatic activity were shown
comparable to that of human defensins and lysozyme.
Despite the potential advantages, delivery of SLPI to the lungs has proven unimpressive [222].
Aerosolisation of recombinant SLPI (100mg) twice daily to individuals with cystic fibrosis was
associated with reduced NE activity on the respiratory epithelial surface, as well a reduction
in the level of IL-8 and neutrophil numbers [223]. However, a greater concentration of
recombinant SLPI compared to AAT is required to suppress NE activity in individuals with
lung disease. Furthermore accumulation of recombinant SLPI on respiratory epithelial
surfaces does not occur and SLPI does not penetrate significantly into the interstitium
following aerosolization. Further drawbacks include the fact that most of the anti-NE effects
are gone within 12 hours of administration. Reasons for this latter phenomenon have been
proposed and may be due to uptake of SLPI by epithelial cells and macrophages, and/or
binding of recombinant SLPI to molecules in the interstitium after passing through the
epithelium [222, 224].
More recently, it has also been shown that SLPI is vulnerable to degradation and inactivation
by cysteinyl cathepins [225] and NE [21], and thus the utilization of SLPI as effective therapy
for COPD presents some challenges. One approach to this challenge is delivery of recombinant
SLPI via a liposomal carrier which protects the activity of SLPI against cathepsin L mediated
degradation, whilst having no adverse effect on SLPI access to intracellular sites of action in
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vitro [226]. Alternatively, co-treatment of SLPI with surfactant protein A has been proposed,
which aids in the preservation of SLPI and protects it from cleavage by matrix metalloproteases
[227].
4.5. Synthetic and semi-synthetic engineered protease inhibitors as alternative therapies for
COPD
In  a  COPD  animal  model,  ADAM-17  (a  membrane  bound  MMP)  has  been  shown  to
contribute to progression of COPD lung disease through activation of TNFα [228]. Recent
studies have demonstrated that AAT, a natural serine protease inhibitor,  also acts as an
ADAM-17  inhibitor  thereby  regulating  soluble  immune  complex  induced  neutrophil
chemotaxis  [148]  and  TNFα  production  in  lung  endothelial  cells  [229].  However,  other
therapeutic  options  for  the  modulation  of  inflammation  associated  with  excessive  pro‐
tease  activity  is  the  use  of  synthetic  or  semi  synthetic  protease  inhibitors.  These  mole‐
cules, for example the non-peptide inhibitor ONO-5046 or sivelestat, offer better accessibility
into the lung milieu due to their reduced size. Sivelestat is a specific inhibitor of NE and
in  LPS  animal  studies  was  shown  to  significantly  reduce  the  number  of  infiltrating
neutrophils and elastase activity levels, thereby decreasing lung tissue damage [230-232].
Moreover, sivelestat has been reported to reduce neutrophil-mediated endothelial cell injury
by inactivating extracellular elastase and by suppressing release of this serine protease by
neutrophils [231]. A recent study demonstrated the ability of sivelestat to inhibit bleomy‐
cin  induced  pulmonary  fibrosis  and  apoptosis  in  human  epithelial  cells  [233].  The  au‐
thors of this study also verified that sivelestat  reduced pulmonary neutrophil  counts by
decreasing BAL fluid levels of cytokine-induced neutrophil chemoattractant (CINC)-1. So
far there have been no in vitro or in vivo investigations on the potential use of sivelestat in
COPD, but studies involving other pulmonary conditions including post-cardiopulmona‐
ry bypass lung injury [234], acute lung injury with sepsis [235] and adult respiratory distress
syndrome [236] have shown some therapeutic success with this synthetic inhibitor. To date,
Japan has been the only country to approve sivelestat for the above conditions [237].
An alternative synthetic inhibitor that has been utilized in several studies is the cyclic thiol
compound MR889. This synthetic inhibitor demonstrated inhibition against several serine
proteases in vitro and in sputum from patients with chronic bronchitis [238]. When used in
clinical studies however, although MR889 was considered safe for COPD patients, the results
demonstrated that there was no significant reduction in the level of biomarkers of lung disease
except for a small subset of individuals who had a short disease duration [239]. Other synthetic
elastase inhibitors such as ZD0892 and FR134043 have been shown to reduce lung inflamma‐
tion associated with cigarette smoke [240, 241] or NE [242] in animal models and in cultured
cells [243]. ZD0892 was shown not to exert an adverse effect on neutrophil function including
uptake and killing of S. aureus, but use of this compound in clinical studies in humans has not
been documented.
More recently, the synthetic selective inhibitor of elastase, AZD9668, has attracted a lot of
attention and was shown to have significant impact on NE activity in vitro [244]. In rodent
models, AZD9668 was shown to prevent NE-induced lung injury, cigarette smoke induced
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inflammatory responses, airspace enlargement and small airways remodelling [244]. Despite
these positive findings however, results of a recent clinical trial involving AZD9668, queried
the efficiency of this inhibitor in COPD patients as no significant change in lung function and
clinical measurements was observed [245]. Although these later results suggest that targeting
NE activity alone may not be an effective treatment option in COPD, a subsequent smaller
study indicated the potential clinical efficacy of AZD9668 in the treatment of bronchiectasis
[246].
Aside from serine proteases, and as already mentioned, MMPs also play a key role in the
development of COPD. TIMPs are endogenous MMP inhibitors and in COPD, MMP activity
levels associated with lung disease are not counteracted by TIMPs [247]. To date no native
TIMPs have been used as potential therapeutics, but synthetic and selective MMP inhibits have
been well documented. The orally administered MMP-9 and MMP-12 inhibitor AZD1236 was
well tolerated by patients in two separate clinical trials but overall it was deemed to have no
effect on clinical parameters [248] or disease related biomarkers in COPD patients [249]. In a
recent study by Wu et al., several potential MMP-12 inhibitors were analysed in vivo, with one
specific inhibitor, Compound 26, modulating cell infiltration into the lungs of mice with
MMP-12 induced inflammation [250]. Similar findings were observed for a second MMP-12
inhibitor, Compound 14 [251]. An additional in vivo study involved the use of the broad
spectrum MMP inhibitor RS113456, which possessed comparable anti-inflammatory proper‐
ties to AAT [252]. In the latter study the authors noted multi-facetted attributes of RS113456,
whereby this MMP inhibitor reduced neutrophil influx, modulated NFκB activity and reduced
MCP-1 and MIP-2 expression in the short term [252].
Other synthetic MMP inhibitors evaluated in cigarette smoke induced models of COPD have
shown significant reductions in lung macrophage numbers [126], neutrophilia [253, 254],
elastase/ MMP levels [254], air space enlargement [126, 254] and inflammatory markers [90,
126]. To date the benefits of MMP inhibitors has only been assessed in animal models and their
successful use as therapeutics for treatment of COPD in humans has not been reported. Thus
caution needs to be exercised due to the potential for tumour growth promotion as a result of
inhibition of angiogenesis factors [255].
An alternative to synthetic inhibitors is the production of semi-synthetic protease inhibitors.
These agents are created through the chemical modification of naturally occurring protease
inhibitors. One such semi-synthetic inhibitor is the engineered protein inhibitor of human NE
(EPI-HNE-4) which is derived from the Kunitz type domain from the naturally occurring inter
α inhibitor. EPI-HNE-4 has been shown resistant to degradation by both human and bacterial
MMPs and its antiprotease activity was reported impervious to oxidative inhibition [256].
Further studies involving the use of a rat model and sputum from cystic fibrosis patients
demonstrated the anti-NE capacity of EPI-HNE-4 along with its ability to decrease neutrophil
migration towards the bacterial peptide N-formyl-L-methionyl-L-leucyl-phenylalanine [257].
Subsequently however, contrary data on the immuno-regulatory effects of this inhibitor have
been documented as Honoré et al., demonstrated that EPI-HNE-4 had little effect on neutrophil
migration or impact on bacterial clearance in a P. aeruginosa model of pneumonia [258].
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Within this expanding field of potential antiprotease therapies lies the development of novel
chimeras that are active against NE, PR3 and CathG. A study by Zani et al., reported on the
development of a chimera consisting of domains from both elafin and SLPI and a trappin-2
variant (A62L) [259]. The authors demonstrated that both A62L and the elafin-SLPI chimera
retained their polypotent inhibition of protease activity while covalently cross-linked to
fibronectin or elastin by a tissue transglutaminase, in a similar fashion to wild-type elafin and
trappin-2 [188]. A recent extensive study on A62L in an epithelial cell line demonstrated that
this engineered trappin-2 molecule prevented neutrophil and protease induced epithelial cell
injury by inhibiting cell detachment, tight junction disruption and ultimately reducing
apoptosis [260]. Although the preliminary data has been generated for these engineered
antiproteases, overall their effect on the inflammatory status and clinical parameters in COPD
patients remains to be investigated.
5. Conclusion
Extensive studies have been performed to extend our knowledge of the involvement of
proteases in respiratory manifestations of COPD, the outcome of which has served to illustrate
the multifactorial complexity of the disease (Figure 2). Nevertheless, this clinical and scientific
knowledge has advanced the design of both fundamental and novel therapeutic strategies,
directed at relieving the protease burden associated with this disorder (Table 2). There have
been major advances in the evaluation of AAT augmentation therapy in the treatment of the
lung disease associated with AAT deficiency with newer focus on aerosolization approaches.
These studies will inevitably show within the next number of years whether this approach
works clinically. No single treatment that effectively prevents activity of the broad spectrum
of proteases present in the airways is available as yet. Such pharmacological approaches
including the development of antiprotease chimeras would essentially correct lung disease
processes and conceivably exert anti-inflammatory effects. However, this would require a
more complete understanding of the mechanism of disease and of the action of presently
accessible and newly discovered drugs.
Protease Role in COPD pathogenesis Inhibitors and
inactivators
Clinical trials and evidence for
antiproteases as therapeutics
















therapy of AAT.(Multiple Clinical
Trials in Humans, see Table 1)
Clinical effects of IV AAT in
AATD:
Slows rate of FEV1 decline
Reduces elastin degradation
Reduces exacerbation frequency
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Protease Role in COPD pathogenesis Inhibitors and
inactivators
Clinical trials and evidence for
antiproteases as therapeutics
Induces IL-8 expression in
bronchial epithelial cells




production of cathepsin B and
MMP-2
Induces expression of MUC5AC















Attenuates loss of lung density
Clinical effects of aerosolized
AAT:
Restores anti-NE capacity (176,
177)
Improved neutrophil killing of
P. aeruginosa (179)
Outcome of phase III clinical trial
pending (NCT 0217671)
SLPI – Reduced NE activity and
reduced IL-8 levels in CF patients
(223)
Sivelestat – Reduced number of
neutrophils in BAL.
Has shown therapeutic benefit in
acute lung injury and ARDS, but
no trials in COPD to date
(230-232, 235, 236)
MR889 – Safe but no significant
reduction in the level of
biomarkers of lung disease in
COPD patients (239)
ZD0892 & FR134043 – Reduce
cigarette induced lung
inflammation, but no human
trials to date (240,2410)
AZD9668 – Decreased NE activity
in vitro (244)
No change in clinical parameters
in COPD (245)










Alpha-1 antitrypsin (AAT) See above for clinical effects of
AAT therapy in AATD and COPD
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Protease Role in COPD pathogenesis Inhibitors and
inactivators
Clinical trials and evidence for
antiproteases as therapeutics
Cathepsin G Proteolysis and destruction of
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neutrophilic inflammation but
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Protease Role in COPD pathogenesis Inhibitors and
inactivators
Clinical trials and evidence for
antiproteases as therapeutics
Degradation of collagens,
elastin, gelatin and fibronectin
Tissue inhibitors of
metalloproteases (TIMP)
Table 2. Summary table listing the various proteases, their targets, their inhibitor/inactivators, and clinical trials.
Figure 2. The effect of protease activity on the pathophysiology of COPD. A diagramatic illustration of the pri‐
mary effects of excessive protease activity on inflammation in COPD. The effects include activation of signalling path‐
ways and proteases, to cleavage and degradation of matrix proteins and antiproteases. The secondary effect of the
excessive protease burden in the COPD lung can result in tissue destruction/ remodelling and excessive cytokine and
mucin production. Consequenrly proteases play a key role in emphysema, neutrophil influx, inflammation, mucus pro‐
duction and infection. As shown by the red lines, antiprotease therapy (AAT, SLPI and elafin) can impact on several
aspects of this complex and intertwined pathway and potentially modulate disease progression.
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